High Ambitions For EU DARWIN Platform After Delivery Of First RWE Studies

29 Mar 2023

Within one year of its establishment, DARWIN EU has started reaping benefits for EU drug regulators commissioning studies using real-world data to better understand diseases, populations and the uses and effects of medicines. The studies can be performed faster, cheaper and at increased capacity.

Futuristic programming code and big data connections and network patterns. 3D illustration. — RWE Can Contribute To More Data-Driven Regulatory Decision Making • Source: Alamy

The European Medicines Agency says efforts are afoot to further strengthen the new EU-wide platform for generating real-world evidence (RWE) – the Data Analysis and Real World Interrogation Network (DARWIN EU), which has already completed its first set of studies commissioned by the agency.

“DARWIN EU has ambitious plans for 2023” during which it will “onboard ten additional data partners and initiate around 16...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

New EU Filings

23 Jun 2025

• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

20 Jun 2025

• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.